Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has approved PAPZIMEOS(tm) (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).
